OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
28 May 2009
Novartis AG has agreed to buy Ebewe Pharma's injectables unit for $1.2 billion in an all-cash transaction.
The deal excludes Ebewe's neurological products business but will enable Novartis to add generic cancer drugs to its offerings.
Ebewe, based in Austria, generated EUR 188 million in sales last year and EUR 53 million in operating profit.